Investigational drug · Phase 3
DEP114
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Persistent Allergic Rhinitis, Allergic Rhinitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "DEP114"
First trial start
2025
Feb 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- EMS2
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DEP114", any sponsor or status.
Conditions studied
As listed on its trial records.
- Persistent Allergic Rhinitis
- Allergic Rhinitis
Approved drugs for the same conditions: Allergies (allergic rhinitis)
Largest trials
Live from ClinicalTrials.gov: studies naming "DEP114" as an intervention, largest first.
- Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.Pivotal-lookingNot yet recruiting
EMSIndustry
NCT06272409 · 318 participants (planned) · Start Feb 15, 2025 · Primary completion Mar 15, 2025
Drug: DEP114; Desloratadine 0.5 MG/ML · For: Allergic Rhinitis
- A Study to Evaluate DEP114 for the Treatment of Acute Exacerbation of Persistent Allergic Rhinitis in Children Aged 6 to Under 12 YearsPivotal-lookingNot yet recruiting
EMSIndustry
NCT07835074 · 316 participants (planned) · Start Jun 2027 · Primary completion Dec 2028
Drug: DEP114; Desloratadine · For: Persistent Allergic Rhinitis
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.